Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Combination Treatment May Prolong HIV Viral Suppression
Clinical Breakthroughs

Combination Treatment May Prolong HIV Viral Suppression

By Melissa RohmanSep 9, 2021
Share
Facebook Twitter Email
Elena Martinelli, PhD, MPH, research professor of Cell and Developmental Biology, was senior author of the study published in Science Translational Medicine.

A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine.

“This really demonstrates that that we should combine broadly neutralizing antibodies with other immunostimulatory agents, especially those that may impact immune response. If we want to use broadly neutralizing antibodies to cure, we need to find the right combination,” said Elena Martinelli, PhD, MPH, research professor of Cell and Developmental Biology and senior author of the study.

Neutralizing antibodies, a key component of the body’s adaptive immune response in fighting against viruses and other pathogens, bind to the surface of infected cells and inhibit them from interacting with and infecting healthy host cells. Previous research has shown that these broadly neutralizing antibodies can promote the body’s immune response, specifically by increasing T-cell and antibody responses in patients diagnosed with HIV.

Additionally, past research efforts led by Martinelli discovered that cells which express the cellular receptor Integrin alpha 4 beta 7 are more commonly infected by HIV and promote pathogenesis. Understanding exactly how an individual’s immune response reacts in the presence of neutralizing antibodies is essential to developing novel therapeutic interventions for treating HIV, according to Martinelli.

For the current study, investigators administered anti-HIV broadly neutralizing antibodies (bNAbs) or a combination of bNAbs and an anti-alpha 4 beta 7 monoclonal antibody in animal models of HIV-infection.

Overall, the combination therapy group demonstrated lower viral load — the amount of a virus present in bodily fluids — until the end of the study’s follow-up period compared to the group that received bNAbs alone.

The study underscores the therapeutic potential in using a combination of neutralizing antibodies and immunostimulatory agents to increase immune response for patients with HIV, according to Martinelli. As for next steps, Martinelli said it will be essential to study the combination treatment administered in additional models of HIV-infection that also received HIV antiretroviral therapy.

“There is a lot of work right now trying to make these antibodies more potent and make them last longer, which is great, but I also think there is space to improve the functionality of these antibodies by combining them with other immunostimulatory agents,” Martinelli said.

Thomas Hope, PhD, professor of Cell and Developmental Biology, of Obstetrics and Gynecology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of the study.

This work was supported by the National Institute of Allergy and Infectious Diseases grant R01AI098546-06.

Cell and Developmental Biology HIV/AIDS Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.